The post RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next? appeared on BitcoinEthereumNews.com. Secretary of Health and Human Services Robert F. Kennedy Jr. The Associated Press Tylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop there. Tylenol may be only the beginning. For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and Human Services, he’s begun turning his opinions into public policy. His Make American Healthy Again initiative has already made it harder for people to get vaccinated against COVID-19 and pushed unverified claims about Tylenol, and he’s just getting started. So what might be next? Kennedy’s already told us. On Monday, Kennedy and FDA Commissioner Marty Makary wrote in a letter to 22 Republican attorneys general that the FDA was reviewing evidence about the safety of abortion drug, mifepristone, which is used in nearly two-thirds of medical abortions. If access to the pill were restricted, it would significantly cut back on abortion access. Another big target: antidepressants. During Kennedy’s confirmation hearings, he falsely claimed that people have a harder time stopping the use of serotonin-based antidepressants “than people have getting off of heroin.” He’s also made the unfounded claim that teenagers who use them are more likely to commit school shootings (they aren’t.) One of the goals of Kennedy’s “Make America Healthy Again” movement is to “assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors.” Any restrictions on them would be a grave concern to the approximately 11% of the population that uses them to treat depression, anxiety and other issues. Another frequent target of Kennedy’s are statins, which more than 92 million Americans… The post RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next? appeared on BitcoinEthereumNews.com. Secretary of Health and Human Services Robert F. Kennedy Jr. The Associated Press Tylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop there. Tylenol may be only the beginning. For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and Human Services, he’s begun turning his opinions into public policy. His Make American Healthy Again initiative has already made it harder for people to get vaccinated against COVID-19 and pushed unverified claims about Tylenol, and he’s just getting started. So what might be next? Kennedy’s already told us. On Monday, Kennedy and FDA Commissioner Marty Makary wrote in a letter to 22 Republican attorneys general that the FDA was reviewing evidence about the safety of abortion drug, mifepristone, which is used in nearly two-thirds of medical abortions. If access to the pill were restricted, it would significantly cut back on abortion access. Another big target: antidepressants. During Kennedy’s confirmation hearings, he falsely claimed that people have a harder time stopping the use of serotonin-based antidepressants “than people have getting off of heroin.” He’s also made the unfounded claim that teenagers who use them are more likely to commit school shootings (they aren’t.) One of the goals of Kennedy’s “Make America Healthy Again” movement is to “assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors.” Any restrictions on them would be a grave concern to the approximately 11% of the population that uses them to treat depression, anxiety and other issues. Another frequent target of Kennedy’s are statins, which more than 92 million Americans…

RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next?

Secretary of Health and Human Services Robert F. Kennedy Jr.

The Associated Press

Tylenol may be only the beginning.

For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and Human Services, he’s begun turning his opinions into public policy. His Make American Healthy Again initiative has already made it harder for people to get vaccinated against COVID-19 and pushed unverified claims about Tylenol, and he’s just getting started. So what might be next? Kennedy’s already told us.

On Monday, Kennedy and FDA Commissioner Marty Makary wrote in a letter to 22 Republican attorneys general that the FDA was reviewing evidence about the safety of abortion drug, mifepristone, which is used in nearly two-thirds of medical abortions. If access to the pill were restricted, it would significantly cut back on abortion access.

Another big target: antidepressants. During Kennedy’s confirmation hearings, he falsely claimed that people have a harder time stopping the use of serotonin-based antidepressants “than people have getting off of heroin.” He’s also made the unfounded claim that teenagers who use them are more likely to commit school shootings (they aren’t.)

One of the goals of Kennedy’s “Make America Healthy Again” movement is to “assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors.” Any restrictions on them would be a grave concern to the approximately 11% of the population that uses them to treat depression, anxiety and other issues.

Another frequent target of Kennedy’s are statins, which more than 92 million Americans take to prevent heart disease and lower cholesterol. Most studies find that statins are both safe and help to prevent serious heart disease, which is the number one killer of Americans.

Yet Children’s Health Defense, the organization Kennedy founded, has published articles questioning the relationship of cholesterol to heart disease, with one calling them “overprescribed and unnecessary.” And earlier this year, as HHS Secretary, Kennedy claimed on a podcast that pharmaceutical companies manipulated studies to show they work.

One of the rationales for the agency’s recent crackdown on pharmaceutical ads is increased uptake of the drugs. Statins were the drugs of an older generation. Also in the crosshairs are newer innovations, like the increasingly popular GLP-1s used to treat diabetes (Ozempic, Mounjaro) and obesity (Wegovy, Zepbound). These drugs have recently been approved for additional health problems, such as sleep apnea, and are even being investigated for drug addiction.

That remarkable success hasn’t stopped Kennedy from criticizing their cost (they are expensive) and making false claims about them. For example, he falsely said that Novo Nordisk, which makes Ozempic, doesn’t market it in Europe. (It does.) He’s also said that ensuring Americans eat a good diet would solve the obesity problem–but multiple clinical studies have shown that GLP-1s are vastly superior to diet alone to helping people not only lose weight but keep it off.

In a first jab at their use, Kennedy rejected a plan to have Medicare cover the cost of GLP-1 drugs for obesity, which would have given 7 million Americans access to them, in April. (Medicare already covers these treatments for diabetes.) Could more restrictions on their use be seen down the road?

“They’re counting on selling it to Americans because we’re so stupid and so addicted to drugs,” Kennedy told viewers of Fox News about Ozempic and its manufacturer Novo Nordisk.

It’s not clear what, if anything, would change his mind.

MORE FROM FORBES

ForbesTrump’s Unproven Claims About Tylenol And Autism Are Reaching Millions On TikTokForbesRFK Jr.’s CDC Is Poised To Restrict Vaccines Even FurtherForbesThis Startup Hit A $3.25 Billion Valuation Building Software To Fix Drug Pricing

Source: https://www.forbes.com/sites/alexknapp/2025/09/26/rfk-jr-is-targeting-vaccines-and-tylenol-are-prozac-and-ozempic-next/

Piyasa Fırsatı
null Logosu
null Fiyatı(null)
--
----
USD
null (null) Canlı Fiyat Grafiği
Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen [email protected] ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

CME Group to Launch Solana and XRP Futures Options

CME Group to Launch Solana and XRP Futures Options

The post CME Group to Launch Solana and XRP Futures Options appeared on BitcoinEthereumNews.com. An announcement was made by CME Group, the largest derivatives exchanger worldwide, revealed that it would introduce options for Solana and XRP futures. It is the latest addition to CME crypto derivatives as institutions and retail investors increase their demand for Solana and XRP. CME Expands Crypto Offerings With Solana and XRP Options Launch According to a press release, the launch is scheduled for October 13, 2025, pending regulatory approval. The new products will allow traders to access options on Solana, Micro Solana, XRP, and Micro XRP futures. Expiries will be offered on business days on a monthly, and quarterly basis to provide more flexibility to market players. CME Group said the contracts are designed to meet demand from institutions, hedge funds, and active retail traders. According to Giovanni Vicioso, the launch reflects high liquidity in Solana and XRP futures. Vicioso is the Global Head of Cryptocurrency Products for the CME Group. He noted that the new contracts will provide additional tools for risk management and exposure strategies. Recently, CME XRP futures registered record open interest amid ETF approval optimism, reinforcing confidence in contract demand. Cumberland, one of the leading liquidity providers, welcomed the development and said it highlights the shift beyond Bitcoin and Ethereum. FalconX, another trading firm, added that rising digital asset treasuries are increasing the need for hedging tools on alternative tokens like Solana and XRP. High Record Trading Volumes Demand Solana and XRP Futures Solana futures and XRP continue to gain popularity since their launch earlier this year. According to CME official records, many have bought and sold more than 540,000 Solana futures contracts since March. A value that amounts to over $22 billion dollars. Solana contracts hit a record 9,000 contracts in August, worth $437 million. Open interest also set a record at 12,500 contracts.…
Paylaş
BitcoinEthereumNews2025/09/18 01:39
Vitalik Buterin Warns Crypto Lost Its Way, But Ethereum Is Ready to Fix It

Vitalik Buterin Warns Crypto Lost Its Way, But Ethereum Is Ready to Fix It

The post Vitalik Buterin Warns Crypto Lost Its Way, But Ethereum Is Ready to Fix It appeared first on Coinpedia Fintech News Ethereum co-founder Vitalik Buterin
Paylaş
CoinPedia2026/01/14 18:13
Top 3 Reasons Why XRP Price Is Surging Today

Top 3 Reasons Why XRP Price Is Surging Today

The post Top 3 Reasons Why XRP Price Is Surging Today appeared on BitcoinEthereumNews.com. The XRP price is back in the spotlight today, becoming one of the top
Paylaş
BitcoinEthereumNews2026/01/14 17:55